CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

NCT04639362 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

85

Enrollment

OTHER

Sponsor class

Conditions

CLL

Interventions

DRUG: ibrutinib, venetoclax, obinutuzumab
DRUG: ibrutinib, venetoclax

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators

[object Object]